BAC and Octapharma to develop custom ligand for recombinant plasma protein
BAC BV announced that it has entered into a collaboration with Octapharma AG. The objective of the collaboration is to discover and develop a custom CaptureSelect(r) ligand for the purification of a recombinant Factor IX product, developed by Octapharma for the prophylaxis and treatment of bleeding in Haemophilia B. Octapharma will use the CaptureSelect ligand in the downstream processing of this protein from mammalian cell lines.
"We have proven that we can design ligands for almost any purification challenge," commented Laurens Sierkstra, CEO of BAC. "Our technology platform enables us to work with our partners to produce affinity media that is custom designed for each individual purification target, meaning that our customers can have absolute confidence that their purification process will be a success. We are very much looking forward to working with Octapharma on this project."
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Lung
HPS_stain

Cross talk between hormone receptors has unexpected effects
Echocardiography
Phoma_draconis
Laeticorticium_roseum
Heat-stable_enterotoxin
Hymenochaete_corrugata
Hebenon
Perenniporia_fraxinea
